Themis Medicare Limited has announced the pledge of 9,20,000 equity shares of Gujarat Themis Biosyn Limited on December 30, 2025, as part of a strategic financial restructuring initiative. The disclosure was made under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, highlighting the company's commitment to regulatory compliance and transparency.

Pledge Details and Financial Structure

The pledge arrangement involves a comprehensive facility cum pledge agreement with Jio Credit Limited for a borrowing amount of ₹10.00 crores. The transaction represents a calculated financial move designed to optimize the company's debt portfolio and reduce overall financing costs.

Shareholding Impact and Ownership Structure

The pledge significantly impacts Themis Medicare's shareholding position in Gujarat Themis Biosyn Limited. Prior to this transaction, Themis Medicare held 2,52,72,037 shares, representing 23.19% of the total share capital of Gujarat Themis Biosyn.

Strategic Financial Restructuring

The pledge arrangement forms part of Themis Medicare's broader financial optimization strategy. The company has specifically stated that the ₹10.00 crore facility will be utilized for repaying existing high-interest-bearing loans, thereby reducing the overall finance cost burden. This approach demonstrates prudent financial management and cost optimization initiatives.

Regulatory Compliance and Disclosure

The disclosure was filed with both the National Stock Exchange of India Limited and BSE Limited on January 2, 2026, ensuring full compliance with regulatory requirements. The transaction was executed under a formal facility cum pledge agreement, providing structured terms and conditions for both parties involved in the arrangement.

The pledge represents a strategic financial decision that balances the need for cost-effective borrowing while maintaining regulatory compliance and transparency standards required for listed entities.

Gujarat Themis Biosyn Limited (GTBL) has marked a significant milestone in its growth trajectory with the commencement of commercial production at its expanded Fermentation Block in Vapi, Gujarat. The company officially began production of Rifamycin-S and Rifamycin-O on October 18, 2025, signaling a substantial boost to its manufacturing capabilities.

Capacity Expansion Details

The expansion project has more than doubled GTBL's fermentation capacity, as detailed in the following table:

This significant increase in capacity positions GTBL to capitalize on growth opportunities within the fermentation segment, particularly in the production of multiple fermentation products.

Strategic Implications

The expansion of the Fermentation Block at Vapi carries several strategic implications for GTBL:

1. Enhanced Production Capabilities: The more than doubled capacity allows GTBL to significantly increase its output of fermentation products.
2. Product Diversification: The expanded facilities enable the company to produce a wider range of fermentation products, potentially opening new market opportunities.
3. Market Position: With increased capacity, GTBL is better positioned to meet growing market demand and potentially increase its market share in the fermentation segment.
4. Operational Efficiency: The new facilities may lead to improved operational efficiencies and economies of scale.

Company's Statement

In its official communication to the stock exchanges, GTBL stated, "With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment."

The commencement of commercial production at the expanded facility marks a pivotal moment for Gujarat Themis Biosyn Limited. As the company leverages its enhanced manufacturing capabilities, stakeholders will be keenly watching how this translates into business growth and market performance in the coming quarters.